1. Home
  2. OKYO

as of 11-13-2026 2:53pm EST

$1.34
$0.05
-3.43%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.

Founded: 2007 Country:
United Kingdom
United Kingdom
Employees: N/A City: N/A
Market Cap: 78.2M IPO Year: 2021
Target Price: $8.33 AVG Volume (30 days): 60.6K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $1.26 - $3.20 Next Earning Date: 07-20-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: